Home › NDC Lookup › RxCUI directory › RxCUI 1595736

Abuse-Deterrent 24 HR hydrocodone bitartrate 20 MG Extended Release Oral Tablet [Hysingla] — RxCUI 1595736

RxNorm drug concept · Semantic branded drug
RxCUI 1595736 Semantic branded drug · SBD ● Current RxNorm concept 6 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1595736
Official nameAbuse-Deterrent 24 HR hydrocodone bitartrate 20 MG Extended Release Oral Tablet [Hysingla]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asHysingla ER 20 MG 24 HR Extended Release Oral Tablet; Hysingla ER 20 MG 24HR Extended Release Oral Tablet
FDA products mapped6
Package NDCs mapped6
Reported Medicaid activity (SDUD)1,748 prescriptions · 11 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Hydrocodone: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Hydrocodone extended-release is for severe, persistent pain that needs an around-the-clock opioid when other treatments haven't worked or aren't enough. It isn't meant for as-neede...
  • Swallow it whole, by mouth. Never crush, chew, cut or dissolve it, since that can release a dangerous dose at once. The capsules are taken about every 12 hours and the tablets once...
  • No. Alcohol can raise hydrocodone levels and cause a potentially fatal overdose. Avoid alcohol-containing products too, and check with me before combining it with sleep aids, anxie...
  • Nausea, constipation, vomiting, dizziness, headache, sleepiness and fatigue are the most common. Call for help right away if breathing slows, you can't stay awake, or you faint.
📖 Read our full Hydrocodone guide →

🕸️ Concept Web — How Abuse-Deterrent 24 HR hydrocodone bitartrate 20... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Abuse-Deterrent 24 HR hydrocodone bitartrate 20 MG Extended Release Oral Tablet [Hysingla] RxCUI 1595736

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Hydrocodone 5489
    • Hydrocodone bitartrate 142439
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Hysingla 1595731
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Hydrocodone Extended Release Oral Tablet 1595729
    • Hydrocodone bitartrate Extended Release Oral Tablet 2645576
    • Hydrocodone Oral Product 1163405
    • Hydrocodone Pill 1163406
    • Hydrocodone bitartrate Oral Product 2659675
    • Hydrocodone bitartrate Pill 2663344
    • Hydrocodone Extended Release Oral Tablet [Hysingla] 1595733
    • Hydrocodone bitartrate Extended Release Oral Tablet [Hysingla] 2657353
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Abuse-Deterrent 24 HR hydrocodone bitartrate 20 MG Extended Release Oral Tablet SCD · 1595730
  • Hydrocodone bitartrate 20 MG SCDC · 1442533
  • Hydrocodone Extended Release Oral Tablet SCDF · 1595729
  • Hydrocodone bitartrate Extended Release Oral Tablet SCDFP · 2645576
  • Hydrocodone Oral Product SCDG · 1163405
  • Hydrocodone Pill SCDG · 1163406
  • Hydrocodone bitartrate Oral Product SCDGP · 2659675
  • Hydrocodone bitartrate Pill SCDGP · 2663344

Brand-Name Concepts

  • Hydrocodone bitartrate 20 MG [Hysingla] SBDC · 1860217
  • Hydrocodone Extended Release Oral Tablet [Hysingla] SBDF · 1595733
  • Hydrocodone bitartrate Extended Release Oral Tablet [Hysingla] SBDFP · 2657353
  • Hysingla Oral Product SBDG · 1595734
  • Hysingla Pill SBDG · 1595735
  • Hysingla BN · 1595731

📦 FDA Products & Package NDCs

6 products · 6 package NDCs
6 package NDCs map to RxCUI 1595736 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
59011-0271-60 60 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (59011-271-... Hysingla ER Knoa Pharma LLC 2015-01-15
59011-0272-60 60 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (59011-272-... Hysingla ER Knoa Pharma LLC 2015-01-15
59011-0273-60 60 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (59011-273-... Hysingla ER Knoa Pharma LLC 2015-01-15
59011-0274-60 60 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (59011-274-... Hysingla ER Knoa Pharma LLC 2015-01-15
59011-0275-60 60 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (59011-275-... Hysingla ER Knoa Pharma LLC 2015-01-15
59011-0276-60 60 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (59011-276-... Hysingla ER Knoa Pharma LLC 2016-12-02
Observed labelers: Knoa Pharma LLC (6) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.